文献速递肝病

胆汁酸治疗的历史与未来

The history and future of bile acid therapies.
PubMed 文献 · J Hepatol · 2025-06-20

本文综述胆汁酸治疗的历史演变与未来前景:从古代动物胆汁用于肝病,到20世纪后半叶胆汁酸用于胆结石溶解及熊去氧胆酸(UDCA)用于胆汁淤积性肝病;目前UDCA被视为原发性胆汁性胆管炎一线治疗,并用于其他胆汁淤积性疾病;过去二十年核受体激动剂及UDCA衍生物等新药在研。

要点

  • UDCA被视为原发性胆汁性胆管炎的有效一线治疗,也用于原发性硬化性胆管炎和妊娠期肝内胆汁淤积症。
  • 过去二十年,法尼醇X受体激动剂、鹅去氧胆酸衍生物奥贝胆酸及UDCA衍生物等用于多种肝胆疾病在研。
  • 与肠肝胆汁酸循环相互作用的新药研发受到关注,用于罕见的遗传性儿科疾病。

核心结论

  • 本文基于数百年至数千年的历史发展,综述胆汁酸治疗在成人、儿童及妊娠期肝胆疾病中的现状与未来前景。

研究设计与样本

  • 本文为综述,检索范围未在摘要中报告。

主要发现

  • 古代东方文化中动物胆汁被视为肝病的潜在疗法已有数千年。
  • 20世纪后半叶开始应用胆汁酸(胆汁主要有机成分)溶解胆结石,并应用熊去氧胆酸(UDCA)治疗胆汁淤积性肝病。
  • 目前UDCA被视为原发性胆汁性胆管炎(最常见的慢性胆汁淤积性肝病)的有效一线治疗,也用于其他胆汁淤积性疾病,包括原发性硬化性胆管炎和妊娠期肝内胆汁淤积症。
  • 过去二十年,核受体激动剂(如法尼醇X受体激动剂及鹅去氧胆酸衍生物奥贝胆酸)以及UDCA衍生物(如去甲熊去氧胆酸及多种UDCA杂合物)一直在研究用于治疗多种良性和恶性、遗传性和获得性肝胆疾病。
  • 与肠肝胆汁酸循环相互作用的新药研发受到关注,用于罕见的遗传性儿科疾病。

关键数值与推荐

  • UDCA被视为原发性胆汁性胆管炎的有效一线治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Animal bile has been regarded as a potential remedy for liver diseases for millennia in ancient Eastern cultures. The application of bile acids, as major organic components of bile, for gallstone dissolution and of ursodeoxycholic acid (UDCA) for cholestatic liver diseases began in the second half of the 20th century. Currently, UDCA is regarded as an effective first-line treatment for primary biliary cholangitis, the most common chronic cholestatic liver disease, and is also applied in other cholestatic disorders, including primary sclerosing cholangitis and intrahepatic cholestasis of pregnancy. For the past two decades, nuclear receptor agonists - such as the farnesoid X receptor agonist and the chenodeoxycholic acid derivative obeticholic acid - as well as derivatives of UDCA, such as norucholic acid and various UDCA hybrids, have been under investigation for the treatment of a wide range of benign and malignant, genetic and acquired hepatobiliary disorders. The development of new drugs that interact with the enterohepatic bile acid circulation has attracted attention for rare genetic paediatric disorders. In the present review, we describe the current status and future prospects of bile acid-based therapies for hepatobiliary diseases in adults, children, and during pregnancy, on the basis of historical developments over centuries and millennia.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Beuers U, Banales JM, Karpen SJ, et al. The history and future of bile acid therapies. J Hepatol. 2025. PMID: 40545045. doi:10.1016/j.jhep.2025.06.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。